Our study provides novel and robust evidence and clinical information, such as incidence rates, for the association between VEGFR-TKIs and AAD occurrence in cancer treatment and may be used as a reference for the safe use of VEGF pathway inhibitors. The gene discussed is VEGFA; the disease is cancer.